Patent ID: 8198469
Filing Date: 2012-06-12
Classification: A61P,C07B,C07C

Abstract:
1. A crystalline form of Tigecycline, designated Form IX, characterized by data selected from the group consisting of a powder XRD pattern with peaks at 5.2, 9.3, 13.1, 13.8, 16.5,18.8, 20.6 and 22.1±0.2 degrees two-theta; a powder XRD pattern as depicted in FIG. 7 ; a solid-state 13 C NMR spectrum with signals at 204.4, 192.8, 177.2, 174.7,and 169.5±0.2 ppm; a solid-state 13 C NMR spectrum having chemical shift differences between the signal exhibiting the lowest chemical shift and another in the chemical shift range of 90 to 210 ppm of 108.6, 97.0, 81.4, 78.9, and 73.7±0.1 ppm; a solid-state 13 C NMR spectrum depicted in FIG. 32 ; and a solid-state 13 C NMR spectrum depicted in FIG. 33 , wherein the signal in the solid-state 13 C NMR exhibiting the lowest chemical shift in the chemical shift range of 90 to 210 ppm is at 95.8±1 ppm.